Specifications of brigatinib/brigatinib

Brigatinib is an oral drug that belongs to the tyrosine kinase inhibitor class and is used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). The following is some specification information for brigatinib:

1. Chemical structure: The chemical name of brigatinib is5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine. The molecular formula is C29H39ClN7O2P, and the corresponding molecular weight is 584.10g/mol. Brigatinib is an off-white to beige/tan solid.

2. Dosage form and dosage: Brigatinib is provided for oral use in the form of film-coated tablets, containing 180 mg, 90 mg or 30 mg of Brigatinib.

3. Usage and dosage: It is usually recommended that adult patients take brigatinib tablets orally once a day. The initial dose is 90 milligrams (mg), with food restrictions required before first use. If the patient tolerates it and needs a dose adjustment, the dose may be gradually increased as directed by the doctor.

4. Storage conditions: Brigatinib should be stored in sealed containers to avoid exposure to humidity and high temperature. It is recommended to store at room temperature and away from children.

5. Precautions: Before using brigatinib, patients should read the drug instructions carefully and follow the doctor's instructions. At the same time, patients should provide their doctors with detailed medical history information and other drugs currently being used to help doctors evaluate whether brigatinib is suitable for use.

In summary, brigatinib is an oral drug used to treatALK-positive non-small cell lung cancer, with different dosage forms and doses available. Before use, consult a physician and follow his or her instructions strictly.